RSAD2

Across TCGA pan-cancer cohorts, RSAD2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RSAD2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RSAD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RSAD2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where RSAD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RSAD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+1.082	<.001	8	view →
LUAD	All	All	−0.231	.010	3	view →
PDAC	All	All	+0.832	.045	2	view →
LSCC	Male	All	+0.224	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RSAD2–HNSC

Open the HNSC breakdown →